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A B S T R A C T 
Background: Neuroblastoma is a malignant solid tumour in children which attacks 
sympathetic nervous system. Despite of increment in its number of incidence, it is still 
rarely investigated. This research aims to improve the understanding of neuroblastoma 
based on the profile of patients, and further, to improve services for patients. 
 
Methods: This was a retrospective study conducted by assessing and descriptively 
analyzed patients medical record. 
 
Results: From 52 patients, 56% were male and 71% were between age of 1-5 years. 
Neuron Specific Enolase (NSE) examination showed that most patients had high levels 
in 29 patients (56%) while Lactate Dehydrogenase (LDH) examination showed that 23 
patients (44%) had low levels. Based on Fine Needle Aspiration Biopsy (FNAB) 
examination, 22 patients (42%) showed formation of malignant round cell tumor. 
Meanwhile, through Bone Marrow Aspiration (BMA) examination, it was found that the 
tumors had already spread to bone marrow in 17 patients (33%). 
 
Conclusions: Based on tumor markers and pathological finding, this study revealed that 
the majority of neuroblastoma patients had poor prognosis. 
 
 
 
INTRODUCTION 
 
Neuroblastoma is an embryonal tumor on the 
sympathetic nervous system that emerged in the early 
fetal and post-natal fetus from sympathetic cells derived 
from the neural crest (1,2). Neuroblastoma is the most 
common extracranial solid tumor in childhood that is 
often diagnosed during the first 10 years of life, and is 
responsible for 11% of pediatric cancer deaths in 
patients younger than 15 years of age (3).  
Since 1984, Japan is the only country which held 
mass screening as a national policy for neuroblastoma. 
But after studies from Germany and Canada in 2002, a 
mass screening for neuroblastoma showed no mortality 
reduction and then it was being halted (4). So, universal 
screening has not detected poor prognosis disease in 
general (5). 
There are around 11000 childhood cancer cases each 
year in Indonesia. Based on the Early Detection 
Installation and Health Promotion of Dharmais Cancer 
Hospital, there were 15 new cases and 7 deaths with 
neuroblastoma from 2010-2013. In developing countries 
like Indonesia, the prognosis in children diagnosed with 
cancer is much slower. Inadequate equipment and 
drugs in hospitals, the occurrence of complications of 
the disease, and the lack of knowledge related to cancer 
in primary health care providers can affect the 
effectiveness of cancer treatment (6). 
Neuroblastoma is a solid tumor characterized with 
spectrum of histopathologic features and 
heterogeneous clinical phenotypes. Accurate clinical 
staging and risk assessment based on clinical, surgical, 
biological and pathological criteria are of pivotal 
importance in assigning prognosis and planning 
effective treatments. To specify patient’s prognosis and 
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outcome, plenty of studies have analyzed the presence 
of several clinicopathological and biological factors 
related to neuroblastoma (7). 
Data on tumor markers and pathological findings 
from neuroblastoma patients in developing countries 
are rarely reported, even though the number of patients 
is quite large. This study was conducted to provide 
observation of the characteristics of tumor markers and 
pathological findings in neuroblastoma patients to 
determine patient’s prognosis and outcome. 
 
METHODS 
 
      This research is a retrospective descriptive study. It 
focuses on prevalence of neuroblastoma case 
distribution by observation of the medical records. The 
study was approved by the ethics of Dr. Soetomo 
General Hospital Surabaya with number of ethics letter 
599/Panke.KKE/XI/2015 on December 3rd 2015. There 
was no conflict of interest between researchers.  
      Instruments used in this research were medical 
records of neuroblastoma patients in Hematology 
Oncology Division of Pediatric Department in Dr 
Soetomo General Hospital starting from 2010 until 
2015. Research population was all neuroblastoma 
patients. An exclusion criterion in this research was 
incomplete medical record. 
      Variables observed in this research were: Neuron 
Specific Enolase (NSE), Lactate Dehydrogenase (LDH), 
Fine Needle Aspiration Biopsy (FNAB), and Bone 
Marrow Aspiration (BMA). The collected data is 
processed using Microsoft Excel and grouped according 
to predetermined criteria, then described in the form of 
tables and narration. 
 
RESULTS 
 
      There were 52 neuroblastoma patients from January 
2010 until December 2015 period of time. Table 2 
delivers information that most patients have high level 
of NSE examination with percentage of 56%, followed 
by 22 people (42%) that were not examined. Table 3 
represents that LDH level of neuroblastoma patients 
were mostly found in less than normal category with 
percentage of 44%. While 19% of them had normal LDH 
level. Table 4 indicates that malignant round cell tumor 
had the highest frequency in FNAB examination from 52 
patients, approximately 42%, whereas 37% of them did 
not undergo FNAB examination. Table 5 illustrates the 
result of Bone Marrow Aspiration (BMA) examination of 
patients with neuroblastoma. The result showed that 
most patients had a normocell formation (31%), had no 
cell nest (42%), had no rosette formation (48%), and did 
not shows elongated cytoplasm (48%). The final result 
showed that most patients (38%) were diagnosed with 
neuroblastoma. 
 
Table 1. Distribution of sex and age 
 
 
Table 2. NSE Examination 
 
NSE  Frequency (n)  Percentage (%)  
Normal (<16)  1  2  
More than normal  29  56  
No description  22  42  
 
Table 3. LDH Examination 
 
LDH Frequency (n) Percentage (%) 
Normal (313-618) 10 19 
Less than normal 23 44 
More than normal 0 0 
No description 19 37 
 
Table 4. FNAB Examination 
 
FNAB  Frequency (n) Percentage (%)  
Malignant round cell 
tumor  
22  42  
Malignant tumor  3  6  
Metastasis 
neuroblastoma  
3  6  
Malignant spindle 
mesenchymal tumor  
1  2  
Metastasis 
retinoblastoma  
2  4  
No evidence of 
malignancy  
1  2  
Lymphoid immature 
atypic cells  
1  2  
No description  19  37  
 
 
Variable Frequency (n) Percentage (%) 
Sex   
Male 29 56 
Female 23 44 
Age   
<1 years old 4 8 
1-5 years old 37 71 
5-10 years old 10 19 
>10 years old 1 2 
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Table 5. BMA Examination 
 
 
DISCUSSION 
 
The aim of the study was to investigate 
characteristic of tumor markers and pathological finding 
in neuroblastoma patient only by assesing medical 
record. Due to some incomplete data in the medical 
record, the data acquired were limited. From 52 
neuroblastoma patients, it was found that 30 of them 
underwent NSE examination, 29 (56%) of 30 patients 
have increased serum NSE. NSE is an important marker 
in adult neuroendocrine tumors because neuroblastoma 
has certain neuroendocrine properties (7). Increase 
concentrations of serum NSE is widely used as a tumor 
marker to indicate poor prognosis of patients who have 
been diagnosed with neuroblastoma. However, this test 
is generally insensitive due to increasing serum NSE 
which is found on all neuroblastoma stage at diagnosis 
(1). Other research found that NSE had a correlation 
with tumor size at diagnosis (p < 0.001) and tumor 
related death (p < 0.01) in neuroblastoma. In 
neuroblastoma patients, particularly with advanced 
disease, chromoganin A (CgA) and NSE concentrations 
were elevated. Only NSE examination correlated to 
primary tumor size and outcome in neuroblastoma, 
even though both CgA and NSE correlated to genetic 
marker. That study concluded that CgA and NSE are 
clinically valuable tumor markers in neuroblastoma (7).  
Clinical parameters such as stage at diagnosis of 
neuroblastoma, ferritin level, age of the patient, and 
LDH, determine the category of neuroblastoma, as well 
as prediction of the patient's prognosis (8). In general, 
the level of tumor markers had good results to 
determine metastatic relapse or disease progression. 
NSE and LDH level were nearly equal in terms of 
sensitivity in the assessment of local recurrence, but to 
diagnose metastatic recurrence, NSE has a more 
sensitive value (9). 
Other study conducted by Cangemi et al. (10) 
mentioned that in 279 patients, high LDH values 
positively associated with worse prognosis (P < 0.01) 
both in patients with localized and metastatic disease. 
Notably, patients with localized disease with LDH values 
> 1300 IU/mL had 12.9 times greater chance of relapse 
(95% CI: 3.34–49.78; P < 0.001)10. But in this study, 
most of the patient had lower level of LDH (n=23) and 
also had limitation because there were 19 (37%) 
patients without data of LDH examination. Normal or 
decreased level of LDH presumably caused as the 
consequent of chemotherapy. A study by Liu et al. (11) 
describes that 51 patients had decrement of serum LDH 
level after 2 months receiving chemotherapy among the 
173 patients with malignancies, and obtained a 
prominent enhanced survival (11). 
On FNAB examination, it was found that the majority 
of patients (42%) showed a malignant round cell tumor, 
this image may also appear on Ewing's sarcoma, PNET, 
small cell osteosarcoma, mesenchymal 
chondrosarcoma, desmoplastic small round cell tumor, 
rhabdomyosarcoma, olfactory neuroblastoma, 
cutaneous neuroendocrine carcinoma, small cell 
melanoma, small cell carcinoma, and lymphoma (12). 
Thus, ensuring neuroblastoma with only FNAB 
examination is not enough. 
BMA examination of neuroblastoma patients in this 
data showed that the majority of patients who came to 
the hospital were already experiencing metastatic 
neuroblastoma, with the discovery of cell nest in 
patients (33%), rosette formation (27%), and elongated 
cytoplasm (27%). A study in 1998 about BMA 
examination showed rosette formations appeared in 6 
patients among 14 patients (13). Cell nest formation, 
rosette formation, and elongated cytoplasm were 
markers of metastasis in BMA examination. This 
research also found that there were 17 out of the 52 
patients who had experienced the presence of these 
signs, showing a metastasis process with a percentage 
of 33%. 
 
 
 
 
Variable  Frequency (n) Percentage (%)  
Cell Formation 
  
Normocell  16 31 
Hipocell  9 17 
Hipercell  9 17 
Normohipocell  3 6 
Normohipercell  1 2 
No description  13 25 
Cell Nest 
  
(+)  15 33 
(-)  22 42 
No description  15 25 
Elongated cytoplasm  
  
(+)  14 27 
(-)  25 48 
No description  13 25 
Rosette formation 
  
(+)  14 27 
(-)  25 48 
No description  13 25 
Conclusion 
  
Neuroblastoma  20 38 
Non diagnostic  16 31 
Hipoplastic marrow  2 4 
ALL-L1  1 2 
No description  13 25 
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CONCLUSIONS 
 
Based on tumor markers and pathological finding, 
this study revealed that the majority of neuroblastoma 
patients had poor prognosis. Specifically in BMA 
examination, majority of patients showed sign of 
metastasis process. Further studies with more complete 
data are therefore necessary to establish whether 
tumor markers and pathological findings are associated 
with cancer survival and prognosis of the patient, to 
further improve work-up treatment. 
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